Literature DB >> 12951170

An overview of the kallikrein gene families in humans and other species: emerging candidate tumour markers.

George M Yousef1, Eleftherios P Diamandis.   

Abstract

Kallikreins are serine proteases with diverse physiologic functions. They are represented by multigene families in many animal species, especially in rat and mouse. Recently, the human kallikrein gene family has been fully characterized and includes 15 members, tandemly localized on chromosome 19q13.4. A new definition has now been proposed for kallikreins, which is not based on function but, rather, on close proximity and structural similarities. In this review, we summarize available information about kallikreins in many animal species with special emphasis on human kallikreins. We discuss the common structural features of kallikreins at the DNA, mRNA and protein levels and overview their evolutionary history. Kallikreins are expressed in a wide range of tissues including the salivary gland, endocrine or endocrine-related tissues such as testis, prostate, breast and endometrium and in the central nervous system. Most, if not all, genes are under steroid hormone regulation. Accumulating evidence indicates that kallikreins are involved in many pathologic conditions. Of special interest is the potential role of kallikreins in the central nervous system. In addition, many kallikreins seem to be candidate tumor markers for many malignancies, especially those of endocrine-related organs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12951170     DOI: 10.1016/s0009-9120(03)00055-9

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  21 in total

1.  Construction and identification of human tissue kallikrein gene eukaryotic expressing vector.

Authors:  Yong Dai; Wujian Peng; Tiyuan Li; Hong Du; Wenxue Sun; Deheng Chen; Zhuojia Xu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2007-04

2.  Prostate-specific antigen is a "chymotrypsin-like" serine protease with unique P1 substrate specificity.

Authors:  Aaron M LeBeau; Pratap Singh; John T Isaacs; Samuel R Denmeade
Journal:  Biochemistry       Date:  2009-04-21       Impact factor: 3.162

3.  Tissue kallikrein activation of the epithelial Na channel.

Authors:  Ankit B Patel; Julie Chao; Lawrence G Palmer
Journal:  Am J Physiol Renal Physiol       Date:  2012-05-23

4.  Trypsin-like proteolytic contamination of commercially available psa purified from human seminal fluid.

Authors:  Michael L Manning; Maya Kostova; Simon A Williams; Samuel R Denmeade
Journal:  Prostate       Date:  2011-12-28       Impact factor: 4.104

Review 5.  Prostate-specific antigen: an overlooked candidate for the targeted treatment and selective imaging of prostate cancer.

Authors:  Aaron M LeBeau; Maya Kostova; Charles S Craik; Samuel R Denmeade
Journal:  Biol Chem       Date:  2010-04       Impact factor: 3.915

6.  Expression and clinical significance of KLK5-8 in endometrial cancer.

Authors:  Shu Lei; Qi Zhang; Fufen Yin; Xiangjun He; Jianliu Wang
Journal:  Am J Transl Res       Date:  2019-07-15       Impact factor: 4.060

7.  Structural characterization and expression of five novel canine kallikrein-related peptidases in mammary cancer.

Authors:  Katerina Angelopoulou; George S Karagiannis
Journal:  Mamm Genome       Date:  2010-09-19       Impact factor: 2.957

8.  The canine kallikrein-related peptidases 9 and 10: structural characterization and expression in mammary cancer.

Authors:  Katerina Angelopoulou; George S Karagiannis
Journal:  Mamm Genome       Date:  2009-12-02       Impact factor: 2.957

Review 9.  Human plasma kallikrein-kinin system: physiological and biochemical parameters.

Authors:  J W Bryant; Z Shariat-Madar
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2009-07

10.  Structural optimization, biological evaluation, and application of peptidomimetic prostate specific antigen inhibitors.

Authors:  Maya B Kostova; D Marc Rosen; Ying Chen; Ronnie C Mease; Samuel R Denmeade
Journal:  J Med Chem       Date:  2013-06-04       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.